IP Library Granted Patent US 9,309,256
Granted Patent B2
US 9,309,256 · App. 14/697,155 · Granted Apr 12, 2016

Pharmaceutically active dimers linked through phenolic hydroxyl groups

Inventor: Nikhilesh Nihala Singh (Mill Valley, CA)
Assignee: OrphoMed, Inc.
C07D489/02A61K31/137A61K31/167A61K31/485C07C217/64C07C217/70C07C233/16C07C233/43C07D489/00C07D489/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,309,256
App. No.
14/697,155
Granted
Apr 12, 2016
Kind
B2
Abstract

Pharmaceutically active homo-dimers of opioid and other pharmaceutically active agents characterized by a single phenolic hydroxyl group wherein the respective monomers are ether-linked through such groups by an ethylene residue. The dimers share the receptor pharmacology of the corresponding monomer, in particular cases are non-absorbed, and the ether link of the dimers is particularly resistant to metabolism when administered to a subject, all conferring divers advantages relative to the corresponding monomers. Exemplary of the dimers are those of buprenorphine, naloxone, naltrexone, des-venlafaxine, albuterol and acetaminophen.

Claims (14)

1. A homo-dimer compound of a pharmaceutically active agent selected from the group consisting of naloxone, naltrexone, des-venlafaxine and albuterol wherein two such agents are covalently ether-linked through phenolic hydroxyl groups of the agents by an ethylene residue, or a pharmaceutically acceptable salt or solvate thereof.

2. A homo-dimer compound according to claim 1 , wherein the compound is in the form of a pharmaceutically acceptable salt.

3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a dimer compound according to claim 1 or 2 .

4. The pharmaceutical composition of claim 3 , wherein said composition is formulated as an oral tablet or capsule or extended release oral tablet or capsule.

5. A naloxone dimer compound having the Formula:

or a pharmaceutically acceptable salt or solvate thereof.

6. A naltrexone dimer compound having the Formula:

or a pharmaceutically acceptable salt or solvate thereof.

7. A des-venlafaxine dimer compound having the Formula:

or a pharmaceutically acceptable salt or solvate thereof.

8. An albuterol dimer compound having the Formula:

or a pharmaceutically acceptable salt or solvate thereof.

9. A homo-dimer compound of claim 2 , wherein the pharmaceutically acceptable salt is a citric acid salt.

10. A dimer compound of any one of claim 5 , 6 7 or 8 , in a citric acid salt form.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2023
From: ORPHOMED, INC.
To: DIMERX, INC.
Reel/Frame 063610/0911 →
SECURITY INTEREST Recorded Jun 11, 2021
From: ORPHOMED, INC.
To: COMERICA BANK
Reel/Frame 056508/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2016
From: ORPHOMED LLC
To: ORPHOMED, INC.
Reel/Frame 037930/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2015
From: SINGH, NIKHILESH NIHALA
To: ORPHOMED LLC
Reel/Frame 036168/0289 →
Continuity (4)
Provisional Application 61985207 · Apr 28, 2014
Provisional Application 62101768 · Jan 9, 2015
Provisional Application 62176883 · Jan 9, 2015
Related Publication 20150307505A1 · Oct 29, 2015